Skip to content
Open access

Final efficacy and safety data from the Phase I/II ARROW study of pralsetinib in patients with advanced REarranged during Transfection fusion-positive non-small cell lung cancer

Oct 2026 · Journal of Thoracic Disease · Vol 18, pp. 1190 - 1197 · 0 citations · 32 references
Medicine

Abstract

. Final Efficacy and Safety Data From the Phase I/II ARROW Study of Pralsetinib in Patients With Advanced RET Fusion-Positive Non-Small Cell Lung Cancer

Read PDF

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.